The treatment cycle of Ponatinib needs to be personalized according to the type of disease, treatment response, and tolerance. It is usually continued until disease progression or intolerable toxicity occurs.

1. Treatment cycle for different indications

(1) Chronic myeloid leukemia in chronic phase: After obtaining sustained molecular response, it may be considered to reduce the dosage to 15mg/day for long-term maintenance treatment.

(2) Accelerated/rapid change period: Continuous daily treatment of 45mg is required, with a median treatment time of approximately 28 months (range 1-63 months).

2 efficacy evaluation nodes

(1) 3 months: Evaluate hematological reactions and adjust the plan if they do not meet the standards.

(2) 6 months: Evaluate the cytogenetic response, and partially relieved patients can continue medication.

(3) 12 months: Confirm the depth of molecular reactions and decide whether to reduce the dosage.

3 Indications for discontinuation of medication

(1) Disease progression: Hematological or genetic recurrence occurs.

(2) Serious toxicity: irreversible adverse reactions such as arterial occlusion and severe liver injury.

(3) Continuous complete molecular response: Some patients may consider discontinuing medication for observation.